<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603759</url>
  </required_header>
  <id_info>
    <org_study_id>3058</org_study_id>
    <nct_id>NCT00603759</nct_id>
  </id_info>
  <brief_title>COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head &amp; Neck Carcinoma</brief_title>
  <official_title>the Role of COX-2 Inhibitor(CELECOXIB) in Combination With Chemoradiation in Locally Advanced Head &amp; Neck Carcinoma, Phase III Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>department of radiation oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      chemotherapy- and radiotherapy-induced oral mucositis represents a therapeutic challenge
      frequently encountered in cancer patients.This side effect causes significant morbidity and
      may delay or interrupt the treatment plan, as well reduce therapeutic index. cyclo-oxygenase
      2 (COX-2) is an inducible enzyme primarily expressed in inflamed tissues and tumor. COX-2
      inhibitors have shown promise as radio- and chemosensitizer and reduce radio-induced
      toxicities.

      we have conducted a phase III, randomized double blind clinical trial to evaluate the
      toxicity and efficacy of celecoxib, a selective COX-2 inhibitor, administered concurrently
      with chemotherapy, and radiation for locally advanced head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of celecoxib (response rate and local control)</measure>
    <time_frame>30 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>toxicity of celecoxib</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">122</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>100 mg qid</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 cap qid</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stage III/IV (locally advanced) carcinoma of oropharynx, oral cavity, hypopharynx,
             larynx, or nasopharynx

          -  primary treatment with chemoradiation

        Exclusion Criteria:

          -  distant metastasis

          -  incomplete treatment

          -  adjuvant chemoradiation after surgery without apparent tumor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahdi Aghili, MD</last_name>
    <role>Study Chair</role>
    <affiliation>cancer institute center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Chemoradiation</name>
      <address>
        <city>Tehran</city>
        <zip>1419733141</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2008</study_first_submitted>
  <study_first_submitted_qc>January 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2008</study_first_posted>
  <last_update_submitted>January 16, 2008</last_update_submitted>
  <last_update_submitted_qc>January 16, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr mahdi Aghili</name_title>
    <organization>department of radiation and oncology</organization>
  </responsible_party>
  <keyword>COX2 inhibitor</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Cyclooxygenase 2 Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

